Viridian Pharma - VRDN Net earnings per one share for the last twelve months

Viridian Therapeutics (VRDN) relies on the development of antibodies for eye and thyroid therapies, reducing long-term risks. The EPS YoY growth rate (trailing 12 months) visualizes this trend, where the level of -18.30 is the current value. The company's developments make the treatment of ophthalmopathies safer, and the transition to subcutaneous injections is aggressively disrupting established intravenous therapy standards.
VRDN (Viridian Therapeutics): analytical breakdowns and indicator data

To isolate fundamental stability from market noise, it is necessary to analyze the year-over-year dynamics of net earnings per share over the last twelve months. By analyzing the EPS YoY growth rate (trailing 12 months), an investor assesses profit generation efficiency, which is critical for Viridian Therapeutics (VRDN) due to high R&D capital burn and a lack of regular commercial revenue.